Albuquerque Startup Daisy Genomics Raises $2.5M to Advance Precision…

Team S · 2026-01-12T13:58:51.000Z

Daisy Genomics, a precision medicine startup based in Albuquerque, New Mexico, has raised $2.5 million in a growth-stage funding round to accelerate the development and deployment of its AI-enabled genetic analysis platform. The company’s technology combines advanced genomics, machine learning and clinical-grade reporting to help individuals and healthcare providers gain deeper insights into genetic data for personalised treatment decisions, wellness planning and disease prevention. This latest infusion of capital underscores investor confidence in the role of data-driven precision medicine tools to transform healthcare outcomes and patient care pathways. The $2.5 million funding round was led by Blue Venture Fund, with substantial participation from Alpenglow Health, Hawkeye Partners, Camino Capital, Riverside Healthcare Investments, and strategic angel investors who bring expertise in biotechnology, data science and clinical innovation. Proceeds from the round will be used to enhance the company’s AI and analytics capabilities, expand clinical partnerships with major health systems, and accelerate go-to-market efforts aimed at both direct-to-consumer and provider-facing channels. Daisy Genomics says it plans to scale operations and broaden its suite of precision health reports enabling more actionable insights across pharmacogenomics, disease risk stratification and lifestyle optimisation. Founded by CEO Melissa Crounse and CTO Mark Adams, Daisy Genomics develops software and analytic tools that turn raw genetic information into clear, clinically relevant interpretations for personalised health approaches. The company has built a modular platform that integrates genomic data with environmental and lifestyle factors empowering clinicians and consumers with evidence-based insights that can influence screening strategies, therapeutic choices and preventive care plans. With the new funding, Daisy Genomics aims to boost research collaborations, enhance regulatory compliance infrastructure and deliver more granular, AI-augmented predictive models that support precision medicine at scale. The raise is part of a broader trend in the healthcare innovation ecosystem where startups at the intersection of genomics, AI and clinical decision support are attracting capital as precision medicine becomes central to next-generation healthcare delivery. #DaisyGenomics, #PrecisionMedicine, #Genomics, #AIinHealthcare, #HealthTech, #GeneticInsights, #PersonalisedHealth, #BiotechInvestment, #HealthcareInnovation, #StartupFunding, #BlueVentureFund, #DigitalHealth, #ClinicalAI, #GeneticAnalytics

Member Login Get Access

Albuquerque Startup Daisy Genomics Raises $2.5M to Advance Precision… | Newnex